Artivion, Inc. AORT
20.47 USD -0.17 (-0.82%)
At closeNov 10, 2026, 4:05 PM EST
20.47 0.00 0.00%
After hours · Nov 10, 4:05 PM ET
19.21 Day range 20.68
20.10 52-week range 47.63
- YTD
- -55.12%
- 1 year
- -54.49%
News
marketbeat.com Artivion Q3 Earnings Call Highlights Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for…
benzinga.com Canaccord Genuity Maintains Buy on Artivion, Lowers Price Target to $30 Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $40 to $30.
benzinga.com Citizens Maintains Market Outperform on Artivion, Lowers Price Target to $42 Citizens analyst Daniel Stauder maintains Artivion (NYSE:AORT) with a Market Outperform and lowers the price target from $48 to $42.
seekingalpha.com Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
zacks.com Artivion (AORT) Lags Q3 Earnings Estimates Artivion (AORT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
benzinga.com Artivion Q3 2026 Earnings Call Transcript Artivion (NYSE:AORT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com Artivion Narrows FY2026 Sales Guidance from $480.000M-$496.000M to $484.000M-$492.000M vs $490.600M Est Artivion (NYSE:AORT) narrows FY2026 sales outlook from $480.000 million-$496.000 million to $484.000 million-$492.000 million vs $490.600 million estimate.
benzinga.com Artivion Q3 Adj. EPS $0.08 Beats $(0.06) Estimate, Sales $123.800M Beat $120.738M Estimate Artivion (NYSE:AORT) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.06) by 233.33 percent. This is a 50 percent decrease over earnings of $0.16 per…
prnewswire.com Artivion Reports Third Quarter 2026 Financial Results Third Quarter & Recent Business Highlights: Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and…
prnewswire.com Artivion to Participate in Upcoming Investor Conferences ATLANTA, Oct. 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming…
prnewswire.com Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results…
benzinga.com Jefferies Initiates Coverage On Artivion with Buy Rating, Announces Price Target of $31 Jefferies analyst Michael Sarcone initiates coverage on Artivion (NYSE:AORT) with a Buy rating and announces Price Target of $31.
benzinga.com Transcript: Artivion Q2 2026 Earnings Conference Call Artivion (NYSE:AORT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
benzinga.com Canaccord Genuity Maintains Buy on Artivion, Raises Price Target to $40 Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $39 to $40.
marketbeat.com Artivion Q2 Earnings Call Highlights Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines…
seekingalpha.com Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
zacks.com Artivion (AORT) Q2 Earnings Meet Estimates Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.- benzinga.com Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.
prnewswire.com Artivion Reports Second Quarter 2026 Financial Results Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis…
prnewswire.com Artivion to Participate in Upcoming Investor Conferences ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming…
prnewswire.com Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial…
defenseworld.net Fifth Third Bancorp Buys 123,023 Shares of Artivion, Inc. $AORT Fifth Third Bancorp lifted its stake in Artivion, Inc. (NYSE: AORT) by 58,029.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
zacks.com Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
seekingalpha.com Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major…
benzinga.com Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.
benzinga.com Artivion Says FDA Approves Premarket Approval Application For AMDS Hybrid Prosthesis Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket…
prnewswire.com Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug…
prnewswire.com Artivion to Participate in the 2026 Truist Securities MedTech Conference ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming…
gurufocus.com Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to ac
businesswire.com Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction…
prnewswire.com Artivion Completes Acquisition of Endospan Ltd. ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing…
benzinga.com Crude Oil Gains 1%; Fluor Shares Plunge After Q1 Results US stocks traded higher, Nasdaq gained 1.5%. Dow down 0.06%. IT shares up 2.1% while healthcare stocks fell 0.9%. Fluor shares dropped 12% due to weak earnings. Westrock Coffee, Innodata, and Nlight…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Citizens Maintains Market Outperform on Artivion, Lowers Price Target to $48 Citizens analyst Daniel Stauder maintains Artivion (NYSE:AORT) with a Market Outperform and lowers the price target from $53 to $48.
benzinga.com Nasdaq Jumps 200 Points; US Adds 115,000 Jobs In April US stocks rise as Nasdaq gains over 200 points, with tech leading. Nonfarm payrolls beat expectations but unemployment rate remains unchanged. Oil down 0.3%, gold up 0.8%, European and Asian markets…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Needham Maintains Buy on Artivion, Lowers Price Target to $44 Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $58 to $44.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Artivion Lowers FY2026 Sales Guidance from $486.000M-$504.000M to $480.000M-$496.000M vs $495.284M Est Artivion (NYSE:AORT) lowers FY2026 sales outlook from $486.000 million-$504.000 million to $480.000 million-$496.000 million vs $495.284 million estimate.
benzinga.com Artivion Q1 Adj. EPS $0.08 Beats $0.05 Estimate, Sales $116.337M Beat $115.803M Estimate Artivion (NYSE:AORT) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.05 by 60 percent. This is a 33.33 percent increase over earnings of $0.06 per share…
benzinga.com UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday Dow Jones falls 250 points as UnitedHealth Group rises on Medicare reimbursement boost, other stocks also see gains in today's session.
benzinga.com Earnings Scheduled For February 12, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Earnings Scheduled For May 5, 2025
- benzinga.com Earnings Scheduled For February 24, 2025
- benzinga.com Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga.com Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday - benzinga.com Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.
- benzinga.com Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.